<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468986</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012011034</org_study_id>
    <nct_id>NCT02468986</nct_id>
  </id_info>
  <brief_title>Study of Venous Endothelial Cells in Rheumatoid Arthritis</brief_title>
  <official_title>Analysis of Endothelial Cells in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart disease is the major contributor of early death in rheumatoid arthritis (RA) and is not
      influenced by traditional risk factors. Blood vessel dysfunction has been associated with
      heart disease and complications such as heart attack. The vessel dysfunction is thought to be
      mediated in part to inflammation. RA patients have evidence of vessel dysfunction seen on
      ultrasound that improves after medications are given.

      The purpose of this study is to evaluate patients with controlled or uncontrolled rheumatoid
      arthritis to determine if there is a difference in the protein expression in the cells that
      line the blood vessels compared to healthy people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a cross sectional analysis of venous endothelial cells in
      rheumatoid arthritis patients who have controlled or uncontrolled disease and healthy
      controls. We will collect venous endothelial cells by placing an IV in antegrade position in
      the forearm and a thin wire will be inserted to collect the cells from the inner lining of
      the vein. The cells will processed and stained for markers of endothelial function and
      oxidative stress including endothelial nitric oxide synthase (eNOS), phospho-eNOS, nuclear
      factor kappa B (NFκB), and nitrotyrosine using immunofluorescence technique. Flow mediated
      dilation (FMD) by ultrasound of the brachial artery on the contralateral arm will be used as
      an additional marker of endothelial function. A blood sample will be taken for analysis of
      inflammatory markers (sedimentation rate, C-reactive protein) and cytokine analysis (IL-1,
      IL-6, TNFa) by cytokine bead array and flow cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial cell protein expression by immunofluorescence microscopy of endothelial nitric oxide synthase, nitrotyrosine, nuclear factor kappa B.</measure>
    <time_frame>Cells are immediately processed following extraction and placed in -80 degree C freezer. Cells are then analyzed by immunofluorescence microscopy in batches of subjects. Patient is followed-up 24 hours after by phone.</time_frame>
    <description>Immunofluorescence microscopy of frozen endothelial cells will be processed in batches to reduce bias. Cells are assessed for individual protein expression at study entry. Repeated collection of cells will not been done.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum cytokines analysis by cytometric bead array</measure>
    <time_frame>Measured once upon enrollment into study. Patient is followed-up 24 hours after by phone.</time_frame>
    <description>Interleukin-1, Interleukin-6, Tumor Necrosis Factor -alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow mediated dilation assessed in the brachial artery by ultrasound</measure>
    <time_frame>Measured once upon enrollment into study. Patient is followed-up 24 hours after by phone.</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Uncontrolled Rheumatoid Arthritis</arm_group_label>
    <description>18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is &gt;3.2 and C-reactive protein (mg/dL) elevated above normal range.
Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP &gt; 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL&gt;160) in the past 6 months; Pregnant or nursing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Rheumatoid Arthritis</arm_group_label>
    <description>18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) &lt;3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP &gt; 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL&gt;160) in the past 6 months; Pregnant or nursing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP &gt; 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL&gt;160) in the past 6 months; Pregnant or nursing.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum collected by serum separator tube. Will be processed and frozen at -80degrees.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis patients will be selected from arthritis clinics associated with UT
        Southwestern Medical Center and Parkland Memorial Hospital. Healthy controls will be
        collected from primary care clinics who refer to these specialty clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Rheumatoid arthritis:

          -  Age 18-75 years

          -  Rheumatoid arthritis defined by 1987 American College of Rheumatology criteria

          -  Attending clinic at University of Texas Southwestern Aston Clinic for Rheumatology or
             Parkland Arthritis Clinic.

        Healthy controls:

        - Age 18-75 years.

        Exclusion Criteria:

        Rheumatoid arthritis:

          -  Insulin dependent diabetes

          -  Cardiovascular or Cerebrovascular disease

          -  Tobacco use in last 24 months

          -  Uncontrolled blood pressure

          -  Uncontrolled cholesterol

          -  Pregnant or nursing

          -  Prednisone greater than 10mg per day

          -  Stable methotrexate dose for less than 4 weeks

          -  Undergoing Infliximab infusions

        Healthy controls:

          -  Insulin dependent diabetes

          -  Cardiovascular or Cerebrovascular disease

          -  Tobacco use in last 24 months

          -  Uncontrolled high blood pressure

          -  Uncontrolled cholesterol

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth B Solow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Karp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth B Solow, MD</last_name>
    <phone>214-648-0419</phone>
    <email>registry@mednet.swmed.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Solow, MD</last_name>
      <phone>214-648-0419</phone>
      <email>registry@mednet.swmed.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Solow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Karp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Solow, MD</last_name>
      <phone>214-648-0419</phone>
      <email>registry@mednet.swmed.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Solow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Karp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004 Jan;63(1):31-5.</citation>
    <PMID>14672888</PMID>
  </reference>
  <reference>
    <citation>Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005 Feb;52(2):402-11. Review.</citation>
    <PMID>15693010</PMID>
  </reference>
  <reference>
    <citation>del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001 Dec;44(12):2737-45.</citation>
    <PMID>11762933</PMID>
  </reference>
  <reference>
    <citation>Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997 Feb 28;129(1):111-8.</citation>
    <PMID>9069525</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol. 2006 May-Jun;24(3):309-12.</citation>
    <PMID>16870100</PMID>
  </reference>
  <reference>
    <citation>Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford). 2008 Dec;47(12):1780-4. doi: 10.1093/rheumatology/ken386. Epub 2008 Oct 14.</citation>
    <PMID>18854346</PMID>
  </reference>
  <reference>
    <citation>Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007 May 25;100(10):1452-9. Epub 2007 Apr 19.</citation>
    <PMID>17446434</PMID>
  </reference>
  <reference>
    <citation>Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998 Jun 30;97(25):2494-8.</citation>
    <PMID>9657467</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

